Turn Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	3.11	0.87	1.18	2.1
Cash & Short-Term Investments	3.11	0.87	1.18	2.1
Cash Growth	-	-26.11%	-43.84%	-
Prepaid Expenses	0.19	0.23	0.02	0.02
Total Current Assets	3.29	1.1	1.2	2.13
Property, Plant & Equipment	0.09	0.12	0.03	0.08
Other Intangible Assets	0.9	0.82	0.77	0.7
Other Long-Term Assets	0.01	0.01	0.01	0.01
Total Assets	4.3	2.05	2.01	2.91
Accounts Payable	2.26	0.67	0.46	0.26
Current Portion of Leases	0.04	0.04	0.03	0.05
Current Unearned Revenue	-	-	-	1.42
Total Current Liabilities	2.31	0.71	0.49	1.72
Long-Term Leases	0.05	0.08	-	0.03
Long-Term Unearned Revenue	1.44	1.44	1.44	-
Total Liabilities	3.79	2.23	1.93	1.76
Common Stock	0	0	0	0
Additional Paid-In Capital	23.22	19.02	17.51	18.37
Retained Earnings	-22.67	-19.2	-17.43	-17.22
Shareholders' Equity	0.5	-0.18	0.09	1.16
Total Liabilities & Equity	4.3	2.05	2.01	2.91
Total Debt	0.09	0.12	0.03	0.08
Net Cash (Debt)	3.01	0.75	1.16	2.02
Net Cash Growth	-	-34.98%	-42.76%	-
Net Cash Per Share	0.11	0.03	0.04	-
Filing Date Shares Outstanding	29.45	26.85	26.49	-
Total Common Shares Outstanding	28.02	26.85	26.49	-
Working Capital	0.99	0.39	0.71	0.4
Book Value Per Share	0.02	-0.01	0.00	-
Tangible Book Value	-0.4	-1	-0.68	0.46
Tangible Book Value Per Share	-0.01	-0.04	-0.03	-
Machinery	-	-	-	0.01

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q